208 related articles for article (PubMed ID: 8236096)
1. Modern treatment of hemophilia: from the shadows towards the light.
Mannucci PM
Thromb Haemost; 1993 Jul; 70(1):17-23. PubMed ID: 8236096
[No Abstract] [Full Text] [Related]
2. [Technic of obtaining the antihemophilic factors VIII and IX and their clinical application].
Triginer J; Vila M; Vicente Arangüena P
Sangre (Barc); 1979; 24(5-C):937-41. PubMed ID: 121169
[No Abstract] [Full Text] [Related]
3. Recombinant factor VIII in hemophilia A: the Canadian experience.
Blanchette VS
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S33-9. PubMed ID: 9351535
[TBL] [Abstract][Full Text] [Related]
4. The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodies.
Engelfriet CP; Reesink HW; Mannucci PM; Gringeri A; Ingerslev J; Brettler DB; Mauser-Bunschoten EP; Negrier C; Berntorp E; Smith OP; Shapiro AD
Vox Sang; 2000; 78(4):256-61. PubMed ID: 10970234
[No Abstract] [Full Text] [Related]
5. [The current therapeutic bases for hemophilia].
Négrier C
Transfus Clin Biol; 2000 Jun; 7(3):257-8. PubMed ID: 10919215
[No Abstract] [Full Text] [Related]
6. Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
Sultan Y; Boyeldieu D; Stieltjes N
Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S59-60. PubMed ID: 8177717
[TBL] [Abstract][Full Text] [Related]
7. Recombinant blood clotting proteins for hemophilia therapy.
Limentani SA; Roth DA; Furie BC; Furie B
Semin Thromb Hemost; 1993; 19(1):62-72. PubMed ID: 8456325
[No Abstract] [Full Text] [Related]
8. Treatment of hemophilia.
Meili EO
Schweiz Med Wochenschr Suppl; 1991; 43():82-9. PubMed ID: 1843043
[No Abstract] [Full Text] [Related]
9. The hemophilias--from royal genes to gene therapy.
Mannucci PM; Tuddenham EG
N Engl J Med; 2001 Jun; 344(23):1773-9. PubMed ID: 11396445
[No Abstract] [Full Text] [Related]
10. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
Hedner U
Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
[No Abstract] [Full Text] [Related]
11. [Recombinant factor VIII].
Tusell JM
Sangre (Barc); 1993 Apr; 38(2):139-42. PubMed ID: 8516727
[No Abstract] [Full Text] [Related]
12. Hepatitis C and pasteurised factor VIII and IX concentrates.
Klarmann D; Kreuz W; Auerswald G; Auberger K; Rabenau H; Gürtler L; Roggendorf M
Thromb Haemost; 1995 Apr; 73(4):736-7. PubMed ID: 7495095
[No Abstract] [Full Text] [Related]
13. Pioneering therapeutic proteins in hemophilia care through innovative technologies.
Pabinger-Fasching I; Négrier C
Thromb Res; 2016 May; 141 Suppl 3():S1. PubMed ID: 27288062
[No Abstract] [Full Text] [Related]
14. Recombinant factor VIII: an introduction.
Büchel KH
Semin Hematol; 1991 Apr; 28(2 Suppl 1):1-4. PubMed ID: 1908119
[No Abstract] [Full Text] [Related]
15. Recombinant clotting factor concentrates.
Lusher JM
Baillieres Clin Haematol; 1996 Jun; 9(2):291-303. PubMed ID: 8800506
[No Abstract] [Full Text] [Related]
16. Recombinant factor VIII: are we really getting more for less?
Gorlin JB; Ewenstein BM
J Pediatr; 1997 Apr; 130(4):507-9. PubMed ID: 9108841
[No Abstract] [Full Text] [Related]
17. The need for recombinant factor VIII: historical background and rationale.
Hilgartner MW
Semin Hematol; 1991 Apr; 28(2 Suppl 1):6-9. PubMed ID: 1908132
[No Abstract] [Full Text] [Related]
18. The current status of recombinant human factor VIII.
Aronson DL
Semin Hematol; 1991 Apr; 28(2 Suppl 1):55-6. PubMed ID: 1908131
[No Abstract] [Full Text] [Related]
19. [New approaches to haemophilia treatment--recombinant and transgenic concentrates, gene therapy and engineered coagulation factors].
Habart D
Cas Lek Cesk; 2006; 145(2):104-11. PubMed ID: 16521398
[TBL] [Abstract][Full Text] [Related]
20. The modern treatment of haemophilia: a narrative review.
Franchini M
Blood Transfus; 2013 Apr; 11(2):178-82. PubMed ID: 22790275
[No Abstract] [Full Text] [Related]
[Next] [New Search]
